Product Overview

Glipizide 10 mg (Generic) is a prescription oral antihyperglycemic medication indicated for the management of Type 2 diabetes mellitus. Manufactured by USV Pvt Ltd, this sulfonylurea agent is supplied in a strip containing ten sustained‑release tablets. The product is available in pack sizes of 60, 90, and 120 tablets, offering flexibility for patients and clinicians seeking long‑term glycemic control.

What is Glipizide 10 mg (Generic)

Glipizide belongs to the sulfonylurea class of antidiabetic drugs. It functions by stimulating pancreatic beta cells to release insulin, thereby reducing fasting and post‑prandial glucose levels. The 10 mg strength represents a standard dose used in adults with Type 2 diabetes who have not achieved adequate control with diet and exercise alone. The formulation is bioequivalent to the branded product and meets the same quality standards set by the U.S. Food and Drug Administration (FDA).

Uses and Benefits

The primary use of Glipizide is to improve glycemic control in adults with Type 2 diabetes mellitus. When combined with a healthy diet and regular physical activity, it helps lower blood glucose concentrations, reducing the risk of diabetes‑related complications such as cardiovascular disease, nephropathy, and retinopathy. Clinical studies have demonstrated that consistent use of Glipizide can achieve target HbA1c levels of less than 7 percent in many patients, supporting long‑term disease management.

Additional benefits include:

• Once‑daily dosing that improves adherence
• Availability in multiple pack sizes to suit individualized therapy
• Cost‑effective generic option without compromising efficacy

These attributes make Glipizide a valuable component of comprehensive diabetes care programs endorsed by the National Institutes of Health (NIH).

How It Works

Glipizide exerts its hypoglycemic effect by binding to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta cells. This interaction closes ATP‑sensitive potassium channels, leading to depolarization of the cell membrane and activation of calcium influx. The resulting rise in intracellular calcium triggers insulin secretion in a glucose‑dependent manner. Because insulin release is modulated by ambient glucose levels, the risk of hypoglycemia is generally lower than with fixed‑dose secretagogues, although it remains a consideration.

Pharmacokinetic data indicate that Glipizide is rapidly absorbed, with peak plasma concentrations occurring within one to two hours after ingestion. The drug is primarily metabolized by the hepatic enzyme CYP2C9, and its elimination is influenced by renal function. The sustained‑release formulation provides a steady plasma concentration over 24 hours, supporting once‑daily administration.

Dosage Guidelines

Initial therapy typically starts with a 5 mg dose taken orally once daily, administered before the first main meal of the day. The dose may be titrated upward in increments of 5 mg at intervals of 1 to 2 weeks, based on glycemic response and tolerability, up to a maximum daily dose of 20 mg. For patients with impaired renal function, a lower starting dose is recommended, and dose adjustments should be made according to the MedlinePlus guidelines.

Special populations, such as the elderly or those with hepatic impairment, may require cautious dose selection. It is essential to monitor blood glucose regularly and adjust the dose as needed to avoid excessive lowering of blood sugar. Patients should be instructed to take the tablet whole, without crushing or chewing, to preserve the sustained‑release properties.

Side Effects

Like all medications, Glipizide can cause adverse effects. The most commonly reported side effects include:

• Hypoglycemia, especially when used in combination with other glucose‑lowering agents
• Weight gain
• Nausea or gastrointestinal discomfort
• Headache

Less frequent but serious adverse reactions may comprise severe hypoglycemia, hepatic enzyme elevations, and hypersensitivity reactions. Patients experiencing persistent gastrointestinal symptoms, unexplained swelling, or signs of an allergic reaction should seek medical attention promptly. For detailed safety information, refer to the Drugs.com monograph.

Warnings and Precautions

Glipizide is contraindicated in patients with a history of hypersensitivity to the drug or any of its inactive ingredients. It should not be used in individuals with Type 1 diabetes or in those with diabetic ketoacidosis. Caution is advised in patients with severe hepatic disease, adrenal or pituitary insufficiency, or those undergoing surgery, as these conditions may increase the risk of hypoglycemia.

Prior to initiation, clinicians should assess renal function, as dose reduction is recommended when the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m². Pregnant or breastfeeding women should only use Glipizide if the potential benefits outweigh the risks, and a discussion with a healthcare provider is essential. Additionally, patients should be aware of the signs of hypoglycemia—such as sweating, tremors, and confusion—and know how to treat them with rapid‑acting carbohydrates.

Drug Interactions

Because Glipizide is metabolized by CYP2C9, drugs that inhibit this enzyme can increase Glipizide plasma concentrations, heightening the risk of hypoglycemia. Examples include certain antifungal agents, sulfonamides, and some angiotensin‑converting enzyme (ACE) inhibitors. Conversely, inducers of CYP2C9, such as rifampin, may decrease Glipizide efficacy. Patients should disclose all concomitant medications, including over‑the‑counter products and herbal supplements, to their healthcare provider.

Storage and Handling

Store Glipizide tablets at room temperature, away from moisture and heat. Keep the medication in its original packaging to protect from humidity. Ensure that the product is out of reach of children and pets. Do not use after the expiration date printed on the strip.

FAQs

What is the recommended starting dose of Glipizide 10 mg (Generic)?

The usual starting dose is 5 mg taken once daily before the first main meal. The dose may be increased gradually based on blood glucose response, but it should not exceed the maximum recommended daily dose of 20 mg.

Can Glipizide be used together with insulin therapy?

Yes, Glipizide can be combined with insulin, but clinicians must monitor blood glucose closely because the combination increases the risk of hypoglycemia. Dose adjustments of either agent may be necessary.

How does Glipizide differ from other oral hypoglycemics?

Glipizide is a sulfonylurea that stimulates insulin release from the pancreas. Unlike metformin, which primarily decreases hepatic glucose production, Glipizide’s mechanism is distinct, and it is often used when metformin is contraindicated or insufficient alone.

Is Glipizide safe for patients with kidney disease?

Glipizide can be used in patients with mild to moderate renal impairment, but dose reduction is recommended for those with an eGFR below 45 mL/min/1.73 m². In severe renal dysfunction, the drug should be avoided unless a physician determines it is appropriate.

Where can I find more detailed prescribing information?

Comprehensive prescribing details are available on the FDA’s drug label database, as well as on reputable sites such as MedlinePlus and NIH.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)